Liquid biopsies in myeloid malignancies

• Main Author: Abdulmawjood, Bilal R.
• Publication Date: 2019
• Other Authors: Roma-Rodrigues, Catarina, Fernandes, Alexandra R., Baptista, Pedro V.
• Format: Other
• Language: eng
• Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Download full: http://hdl.handle.net/10362/127787
• topic: Circulating tumor cells; Circulating tumor DNA; Exosomes; Leukemia; Liquid biopsy; MicroRNAs; Cancer Research; Pharmacology (medical); SDG 3 - Good Health and Well-being

Hematologic malignancies are the most common type of cancer affecting children and young adults, and encompass diseases, such as leukemia, lymphoma, and myeloma, all of which impact blood associated tissues such as the bone marrow, lymphatic system, and blood cells. Clinical diagnostics of these malignancies relies heavily on the use of bone marrow samples, which is painful, debilitating, and not free from risks for leukemia patients. Liquid biopsies are based on minimally invasive assessment of markers in the blood (and other fluids) and have the potential to improve the efficacy of diagnostic/therapeutic strategies in leukemia patients, providing a useful tool for the real time molecular profiling of patients. The most promising noninvasive biomarkers are circulating tumor cells, circulating tumor DNA, microRNAs, and exosomes. Herein, we discuss the role of assessing these circulating biomarkers for the understanding of tumor progression and metastasis, tumor progression dynamics through treatment and for follow-up.